Minglin Zhang

Minglin Zhang

Auto-generated profile, based on publicly available information

Minglin Zhang

Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
MZMinglin Zhang
Minglin Zhang
TLTaolang Li
Taolang Li
JZJiaxing Zhu
Jiaxing Zhu
BTBi-Guang Tuo
Bi-Guang Tuo
XLXuemei Liu
Xuemei Liu
The incidence of colorectal cancer has increased annually, and the pathogenesis of this disease requires further investigation. In normal colorectal tissues, ion channels and transporters maintain the water‐electrolyte balance and acid/base homeostasis. However, dysfunction of these ion channels and transporters leads to the development and progression of colorectal cancer. Therefore, this review focuses on the progress in understanding the roles of ion channels and transporters in the colorectum and in colorectal cancer, including aquaporins (AQPs), Cl− channels, Cl−/ exchangers, Na+/ transporters and Na+/H+ exchangers. The goal of this review is to promote the identification of new targets for the treatment and prognosis of colorectal cancer.

9 March 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
MZMinglin Zhang
Minglin Zhang
ZMZhiyuan Ma
Zhiyuan Ma
ZYZhiqiang Yi
Zhiqiang Yi
HWHu Wang
Hu Wang
JZJiaxing Zhu
Jiaxing Zhu
XLXuemei Liu
Xuemei Liu
Solute carrier family 26 member 9 (SLC26A9) is a member of the Slc26a family of multifunctional anion transporters that functions as a Cl- channel in parietal cells during acid secretion. We explored the role of SLC26A9 in colorectal cancer (CRC) and its related mechanisms through clinical samples from CRC patients, CRC cell lines and mouse models. We observed that SLC26A9 was expressed at low levels in the cytoplasm of adjacent tissues, polyps and adenomas but was significantly increased in colorectal adenocarcinoma. Moreover, increased levels of SLC26A9 were associated with a high risk of disease and poor prognosis. In addition, downregulation of SLC26A9 in CRC cells induced cell cycle arrest and apoptosis but inhibited cell proliferation and xenograft tumor growth both in vitro and in vivo. Mechanistic analysis revealed that SLC26A9 was colocalized with β-catenin in the nucleus of CRC cells. The translocation of these two proteins from the cytoplasm to the nucleus reflected the activation of Wnt/β-catenin signaling, and promoted the transcription of downstream target proteins, including CyclinD1, c-Myc and Snail, but inhibited the expression of cytochrome C (Cyt-c), cleaved Caspase9, cleaved Caspase3 and apoptosis-inducing factor (AIF). CRC is accompanied by alteration of epithelial mesenchymal transition (EMT) markers. Meanwhile, further studies showed that in SW48 cells, overexpressing SLC26A9 was cocultured with the β-catenin inhibitor XAV-939, β-catenin was downregulated, and EMT was reversed. Our study demonstrated SLC26A9 may be responsible for alterations in the proliferative ability and aggressive potential of CRC by regulating the Wnt/β-catenin signaling pathway.

10 November 2025 in International Journal of Surgery
Verified
Journal Article
Open access
TCTing Cai
Ting Cai
XZXuelin Zhao
Xuelin Zhao
HHHai Hu
Hai Hu
FWFen Wang
Fen Wang
MZMinglin Zhang
Minglin Zhang
Background: Helicobacter pylori ( H. pylori ), a Group 1 carcinogen, is linked to gastritis, gastric cancer, and extragastric diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary Sjögren syndrome (pSS), and systemic sclerosis (SSc). Despite these epidemiological associations, the molecular mechanisms underlying their comorbidity remain unclear. Materials and Methods: Integrated transcriptomics were used to identify differentially expressed genes (DEGs) shared between H. pylori and rheumatic diseases, functional enrichment analysis and molecular docking were performed, and hub genes, predicted regulatory transcription factors, and small-molecule drugs were identified. Results: We identified DEGs shared between H. pylori infection and rheumatic diseases, namely 134 (RA), 103 (SLE), 244 (pSS), and 75 (SSc). Functional enrichment revealed the following convergent pathways across diseases: immune activation (in RA and pSS), viral defense (in SLE and SSc), and dysregulated Toll-like/NOD-like receptor signaling. Based on the highest degree scores, hub gene screening prioritized CXCL10, JUN (RA); STAT1, CXCL10, ISG15, and MX1 (SLE); PTPRC, ITGB2, CD19, STAT1, and CXCL10 (pSS); and STAT1, CXCL10, MX1, and OAS1 (SSc). Immune infiltration demonstrated disease-specific dysregulation: M1 macrophages in RA/pSS, monocytes in SLE, and T-cell subsets in SSc. Transcription factor analysis revealed STAT1, RELA, and IRFs to be key regulators, as validated in disease datasets. Drug prediction and molecular docking revealed geldanamycin (targeting IGF1R and JUN in RA), oestriol (OAS family and ISG15 in SLE), atorvastatin (CXCL10 and TLR4 in pSS), and cerivastatin ( TLR4 in SSc) as potential therapeutics. Conclusion: This study revealed the immune/viral pathways and hub genes linking H. pylori to rheumatic diseases, suggesting potential therapeutic targets.